Literature DB >> 11684840

EAU Guidelines on benign prostatic hyperplasia (BPH).

J J de la Rosette1, G Alivizatos, S Madersbacher, M Perachino, D Thomas, F Desgrandchamps, M de Wildt.   

Abstract

OBJECTIVE: To establish guidelines for the diagnosis, treatment, and follow-up of BPH.
METHODS: A search of published work was conducted using Medline. In combination with expert opinions recommendations were made on the usefulness of tests for assessment and follow-up: mandatory, recommended, or optional. In addition, indications and outcomes for the different therapeutic options were reviewed.
RESULTS: A digital rectal examination is mandatory in the assessment for the diagnosis of BPH. Recommended tests are the International Prostate Symptom Score, creatinine measurement (or renal ultrasound), uroflowmetry, and postvoid residual urine volume. All other tests are optional. The aim of treatment is to improve patients' quality of life, and it depends on the severity of the symptoms of BPH. The watchful waiting policy is recommended for patients with mild symptoms, medical treatment for patients with mild-moderate symptoms, and surgery for patients who failed medication or conservative management and who have moderate-severe symptoms, and/or complications of BPH which require surgery. Regarding non-surgical treatments, transurethral microwave thermotherapy is the most attractive option. These treatments should be reserved for patients who prefer to avoid surgery or who no longer respond favourably to medication. Finally, recommendations for follow-up tests and a recommended follow-up time schedule after BPH treatment are provided.
CONCLUSIONS: Recommendations for assessment, possible therapeutic options, and follow-up of patients with BPH are made.

Entities:  

Mesh:

Year:  2001        PMID: 11684840     DOI: 10.1159/000049784

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  50 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

2.  Fluid manipulation among individuals with lower urinary tract symptoms: a mixed methods study.

Authors:  Emily A Elstad; Nancy N Maserejian; John B McKinlay; Sharon L Tennstedt
Journal:  J Clin Nurs       Date:  2010-11-15       Impact factor: 3.036

3.  The effectiveness of a scientific symposium to change urologists' attitude towards treatment of LUTS/BPH.

Authors:  Dionisios Mitropoulos; George Moutzouris; Vaios Papadimitriou; Petros Perimenis; Frank Sofras
Journal:  Int Urol Nephrol       Date:  2007-02-28       Impact factor: 2.370

4.  Extraperitoneal laparoscopic adenomectomy for benign prostatic hyperplasia.

Authors:  Lin-Yu Zhou; Jun Xiao; Hao Chen; Yu-Ping Zhu; You-Wen Sun; Qiang Xuan
Journal:  World J Urol       Date:  2008-12-10       Impact factor: 4.226

5.  Self-management for men with lower urinary tract symptoms.

Authors:  Christian T Brown; Mark Emberton
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

6.  Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients.

Authors:  Carlo Magno; Giuseppe Mucciardi; Alessandro Galì; Giuseppina Anastasi; Antonino Inferrera; Giuseppe Morgia
Journal:  Int Urol Nephrol       Date:  2008-05-14       Impact factor: 2.370

7.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

8.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

9.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

10.  Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.

Authors:  Jae-Seung Paick; Soo Woong Kim; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.